Chemotherapy of metastatic bowel cancer

Hospital Medicine

Volumn 55, Issue 5, 1996, Pages 263-266

  Ross, Paul J ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; METASTASIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 0030571790     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. The Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. J Clin Oncol 10: 896-903
2. The Advanced Colorectal Cancer Meta-analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic Colorectal cancer. J Clin Oncol 12: 960-9
3. Allen-Mersh TG, Earlam S, Fordy C, Abrqams K, Houghton J (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for Colorectal liver metastases. Lancet 344: 1255-60
4. Armand JP, Ducreux M, Mahjoubi M et al (1995) CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-7
5. de Gramont A, Bosset JF, Milan C et al (1995) A prospectively randomized trial comparing 5-fluorouracil bolus with low dose folinic acid (FUFOld) and 5-fluorouracil bolus plus continuous infusion with high dose folinic acid (LV5-FU2) for advancedcolorectal cancer. Proc ASCO 14: 455 (Abstract)
6. Durrant LG, Denton GWL, Jacobs E et al (1992) An idiotypic replica of carcinoembryonic antigen and humoral responses directed against human colorectal tumours. Int J Cancer 50: 811-16
7. Hill M, Norman A, Cunningham D et al (1995a) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13: 1297-302
8. Hill M, Norman A, Cunningham D et al (1995b) The impact of protracted venous infusion 5-fluorouracil with or without interferon-alpha on tumour response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317-23
9. Leichman CG, Fleming TR, Muggia FM et al (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13: 1303-11
10. Levi F, Perpoint B, Garufi C et al (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A: 1280-4
11. Levi FA, Zidani R, Vannetzel J-M et al (1994) Chronomodulated vs fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86: 1608-17
12. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-32
13. Martin JK, O'Connell MJ, Wieand HS et al (1990) Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Sure 125: 1022-7
14. Moreau S, Machover D, de Gramont A et al (1993) Phase II trial of oxaliplatin: 1-OHP in patients with colorectal carcinoma (CRC) previously resistant to 5 fluorouracil (5 FU) and folimc acid (FA). Proc ASCO 12: 645 (Abstract)
15. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10: 904-11
16. Poon MA, O'Connell MJ, Moertel CG et al (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-18
17. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D (1993) Randomised comparison of combination chemotherapy plus best supportive care with best supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752-5
18. Steele G, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D (1991) A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Study Group Protocol 6584. J Clin Oncol 9: 1105-12
19. Wagman LD, Kemeny MMM, Leong L et al (1990) A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8: 1885-93
20. Zalcberg J, Cunningham D, Rath U et al (1995) 'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): first results of a phase III study. (Abstract) Eur J Oncol 31A: 701